CY1111240T1 - Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1 - Google Patents
Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1Info
- Publication number
- CY1111240T1 CY1111240T1 CY20111100117T CY111100117T CY1111240T1 CY 1111240 T1 CY1111240 T1 CY 1111240T1 CY 20111100117 T CY20111100117 T CY 20111100117T CY 111100117 T CY111100117 T CY 111100117T CY 1111240 T1 CY1111240 T1 CY 1111240T1
- Authority
- CY
- Cyprus
- Prior art keywords
- chk1
- hetero
- inhibition
- derivatives useful
- aryl derivatives
- Prior art date
Links
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 title 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000004543 DNA replication Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 230000024321 chromosome segregation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66602605P | 2005-03-29 | 2005-03-29 | |
| EP06748900A EP1869020B1 (en) | 2005-03-29 | 2006-03-29 | Heteroaryl urea derivatives useful for inhibiting chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111240T1 true CY1111240T1 (el) | 2015-06-11 |
Family
ID=36677174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100117T CY1111240T1 (el) | 2005-03-29 | 2011-02-03 | Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8093244B2 (enExample) |
| EP (2) | EP1869020B1 (enExample) |
| JP (2) | JP5117374B2 (enExample) |
| KR (2) | KR100912998B1 (enExample) |
| CN (2) | CN102219784A (enExample) |
| AR (1) | AR056645A1 (enExample) |
| AT (1) | ATE490248T1 (enExample) |
| AU (1) | AU2006230337B2 (enExample) |
| BR (1) | BRPI0609667A2 (enExample) |
| CA (1) | CA2602199C (enExample) |
| CR (1) | CR9395A (enExample) |
| CY (1) | CY1111240T1 (enExample) |
| DE (1) | DE602006018590D1 (enExample) |
| DK (1) | DK1869020T3 (enExample) |
| EA (1) | EA011287B1 (enExample) |
| ES (1) | ES2356068T3 (enExample) |
| HR (1) | HRP20100678T1 (enExample) |
| IL (1) | IL185481A0 (enExample) |
| MA (1) | MA29439B1 (enExample) |
| MX (1) | MX2007012116A (enExample) |
| NO (1) | NO20074944L (enExample) |
| NZ (1) | NZ561458A (enExample) |
| PL (1) | PL1869020T3 (enExample) |
| PT (1) | PT1869020E (enExample) |
| RS (1) | RS51616B (enExample) |
| SI (1) | SI1869020T1 (enExample) |
| TN (1) | TNSN07369A1 (enExample) |
| TW (1) | TWI375559B (enExample) |
| UA (1) | UA92164C2 (enExample) |
| WO (1) | WO2006105262A1 (enExample) |
| ZA (1) | ZA200707715B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5221367A (en) | 1988-08-03 | 1993-06-22 | International Business Machines, Corp. | Strained defect-free epitaxial mismatched heterostructures and method of fabrication |
| WO2008067027A2 (en) * | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
| CN101200429B (zh) * | 2006-12-13 | 2012-08-22 | 上海睿智化学研究有限公司 | 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法 |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| PT3411036T (pt) | 2016-02-04 | 2022-02-21 | Pharmaengine Inc | Pirazóis 3,5-dissubstituídos úteis como inibidores da checkpoint quinase 1 (chk1) e as suas preparações e aplicações |
| JP7158023B2 (ja) | 2016-03-15 | 2022-10-21 | オリソン ヘノミクス エセ． アー． | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
| EP3600247A1 (en) * | 2017-03-31 | 2020-02-05 | Seattle Genetics, Inc. | Combinations of chk1- and wee1 - inhibitors |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| US12404332B2 (en) * | 2020-03-13 | 2025-09-02 | Research Development Foundation | Methods for diagnosing and treating cancers |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293552A (en) | 1978-02-27 | 1981-10-06 | Eli Lilly And Company | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas |
| US6174993B1 (en) | 1997-05-21 | 2001-01-16 | The Children's Medical Center Corp. | Short peptides which selectively modulate the activity of serine/threonine kinases |
| GB9718952D0 (en) | 1997-09-05 | 1997-11-12 | Medical Res Council | Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods |
| US6218109B1 (en) | 1997-09-05 | 2001-04-17 | Baylor College Of Medicine | Mammalian checkpoint genes and proteins |
| DE69818083T2 (de) | 1997-10-06 | 2004-07-08 | Abbott Gmbh & Co. Kg | INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE |
| EP1135135A4 (en) | 1998-09-18 | 2006-08-09 | Smithkline Beecham Corp | CHK1 KINASE INHIBITORS |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| AU3974001A (en) | 2000-02-03 | 2001-08-14 | Ali R. Fattaey | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
| CA2401016A1 (en) | 2000-02-25 | 2001-08-30 | University Of California | Scytonemin and methods of using thereof |
| US6211164B1 (en) | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| US6534691B2 (en) | 2000-07-18 | 2003-03-18 | E. I. Du Pont De Nemours And Company | Manufacturing process for α-olefins |
| ATE295354T1 (de) | 2000-08-18 | 2005-05-15 | Agouron Pharma | Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen |
| NZ527767A (en) | 2001-01-26 | 2004-11-26 | Pharmacia Italia S | Chromane derivatives, process for their preparation and their use as antitumor agents |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| EP1401831A1 (en) | 2001-07-03 | 2004-03-31 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| ATE414697T1 (de) | 2001-10-04 | 2008-12-15 | Smithkline Beecham Corp | Nf-kb-inhibitoren |
| WO2003029241A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2003028731A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2003037886A2 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US20030119839A1 (en) | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
| AU2003224341A1 (en) | 2002-04-26 | 2003-11-10 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
| AU2003243318A1 (en) * | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| US20040034038A1 (en) | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
| US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| HRP20050624A2 (en) | 2003-01-09 | 2006-02-28 | Pfizer Inc. | Diazepinoindole derivatives as kinaze inhibitors |
| WO2006012308A1 (en) * | 2004-06-25 | 2006-02-02 | Icos Corporation | Bisarylurea derivatives useful for inhibiting chk1 |
| CA2679908A1 (en) | 2009-09-23 | 2011-03-23 | Shell Internationale Research Maatschappij B.V. | Closed loop solvent extraction process for oil sands |
| CN104407475B (zh) | 2014-12-04 | 2017-04-05 | 厦门天马微电子有限公司 | 液晶显示面板 |
-
2006
- 2006-03-29 CA CA2602199A patent/CA2602199C/en not_active Expired - Fee Related
- 2006-03-29 TW TW095110859A patent/TWI375559B/zh not_active IP Right Cessation
- 2006-03-29 KR KR1020077022281A patent/KR100912998B1/ko not_active Expired - Fee Related
- 2006-03-29 PL PL06748900T patent/PL1869020T3/pl unknown
- 2006-03-29 JP JP2008504337A patent/JP5117374B2/ja not_active Expired - Fee Related
- 2006-03-29 NZ NZ561458A patent/NZ561458A/en not_active IP Right Cessation
- 2006-03-29 ES ES06748900T patent/ES2356068T3/es active Active
- 2006-03-29 HR HR20100678T patent/HRP20100678T1/hr unknown
- 2006-03-29 EP EP06748900A patent/EP1869020B1/en active Active
- 2006-03-29 CN CN2011101022112A patent/CN102219784A/zh active Pending
- 2006-03-29 DK DK06748900.5T patent/DK1869020T3/da active
- 2006-03-29 AR ARP060101226A patent/AR056645A1/es unknown
- 2006-03-29 MX MX2007012116A patent/MX2007012116A/es active IP Right Grant
- 2006-03-29 AU AU2006230337A patent/AU2006230337B2/en not_active Ceased
- 2006-03-29 RS RS20110053A patent/RS51616B/sr unknown
- 2006-03-29 WO PCT/US2006/011584 patent/WO2006105262A1/en not_active Ceased
- 2006-03-29 EA EA200702094A patent/EA011287B1/ru not_active IP Right Cessation
- 2006-03-29 BR BRPI0609667-0A patent/BRPI0609667A2/pt not_active IP Right Cessation
- 2006-03-29 KR KR1020097002925A patent/KR20090031459A/ko not_active Ceased
- 2006-03-29 SI SI200630870T patent/SI1869020T1/sl unknown
- 2006-03-29 US US11/908,416 patent/US8093244B2/en not_active Expired - Fee Related
- 2006-03-29 EP EP10189889A patent/EP2330105A1/en not_active Withdrawn
- 2006-03-29 CN CN2006800101504A patent/CN101151259B/zh not_active Expired - Fee Related
- 2006-03-29 DE DE602006018590T patent/DE602006018590D1/de active Active
- 2006-03-29 PT PT06748900T patent/PT1869020E/pt unknown
- 2006-03-29 AT AT06748900T patent/ATE490248T1/de active
- 2006-03-29 UA UAA200710711A patent/UA92164C2/ru unknown
-
2007
- 2007-08-23 IL IL185481A patent/IL185481A0/en unknown
- 2007-09-07 ZA ZA200707715A patent/ZA200707715B/xx unknown
- 2007-09-26 CR CR9395A patent/CR9395A/es unknown
- 2007-09-28 TN TNP2007000369A patent/TNSN07369A1/en unknown
- 2007-10-01 NO NO20074944A patent/NO20074944L/no not_active Application Discontinuation
- 2007-10-26 MA MA30325A patent/MA29439B1/fr unknown
-
2009
- 2009-05-20 JP JP2009122107A patent/JP2009227682A/ja active Pending
-
2011
- 2011-02-03 CY CY20111100117T patent/CY1111240T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111240T1 (el) | Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1 | |
| NO20033858D0 (no) | Aryl- og heteroarylurea-CHK1-inhibitorer for anvendelse som radiosensitiviseringsmidler og chamosensitiviseringsmidler | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren | |
| ECSP109953A (es) | Derivados de piridazinona | |
| GT200600143A (es) | Fenilacetamidas apropiadas como inhibidores de la proteina kinasa | |
| EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
| CL2011000957A1 (es) | Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer. | |
| CO6351786A2 (es) | Inkibidores de la cinasa map p38 | |
| EA200601697A1 (ru) | Производные карболина, полезные в ингибировании ангиогенеза | |
| EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
| CU24087B1 (es) | Compuestos de carbazol | |
| MX374896B (es) | Compuestos con actividad anticáncer. | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| CY1113166T1 (el) | Αναστολεις των ενζυμων ενεργοποιησης ε1 | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| CO6361926A2 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales | |
| CY1117504T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1 | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| DOP2006000061A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| UY31775A (es) | Compuestos heterocíclicos como inhibidores de mek | |
| CY1113424T1 (el) | Μεθοδος αντιμετωπισης του καρκινου ή/και παθησεις με κυτταρικη υπερπλασια και παραγοντες που στοχευουν τον αναβολισμο υαλουρονανης για τον ιδιο σκοπο | |
| CY1108266T1 (el) | Παραγωγα διβενζο(c) χρωμεν-6-ονης ως αντικαρκινικοι παραγοντες | |
| WO2006021002A3 (en) | Compounds useful for inhibiting chk1 | |
| UY29036A1 (es) | Derivados de oxopiperidina, su preparacion y su aplicacion en terapeutica |